Bio-Path Holdings Inc. (BPTH) Financial Statements (2025 and earlier)

Company Profile

Business Address 4710 BELLAIRE BOULEVARD
BELLAIRE, TX 77401
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 100,0001,173,000600,0004,006,000188,0001,052,000
Cash and cash equivalent 100,0001,173,000600,0004,006,000188,0001,052,000
Prepaid expense474,0001,074,000531,000274,000632,000632,000
Other current assets1,524,0001,529,0001,806,000739,000817,0001,358,000
Other undisclosed current assets 22,000 (38,000)   
Total current assets:2,120,0003,776,0002,899,0005,019,0001,637,0003,042,000
Noncurrent Assets
Operating lease, right-of-use asset54,00084,00024,00051,00077,000102,000
Property, plant and equipment21,00023,00042,00048,00054,00076,000
Total noncurrent assets:75,000107,00066,00099,000131,000178,000
TOTAL ASSETS:2,195,0003,883,0002,965,0005,118,0001,768,0003,220,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4,429,0003,212,0003,349,0002,955,0003,730,0001,803,000
Accounts payable2,438,0001,274,0001,036,000766,0001,746,000457,000
Accrued liabilities1,991,0001,938,0002,313,0002,189,0001,984,0001,346,000
Debt261,000     
Other undisclosed current liabilities54,00083,00026,00055,00082,000103,000
Total current liabilities:4,744,0003,295,0003,375,0003,010,0003,812,0001,906,000
Noncurrent Liabilities
Liabilities, other than long-term debt     3,00010,000
Operating lease, liability     3,00010,000
Other undisclosed noncurrent liabilities40,000434,000302,000817,000578,000863,000
Total noncurrent liabilities:40,000434,000302,000817,000581,000873,000
Total liabilities:4,784,0003,729,0003,677,0003,827,0004,393,0002,779,000
Equity
Equity, attributable to parent, including:(2,589,000)154,000(712,000)1,291,000(2,625,000)441,000
Common stock8,0006,0004,0002,0001,0001,000
Additional paid in capital117,756,000117,649,000114,032,000113,922,000108,138,000108,047,000
Accumulated deficit(120,353,000)(117,501,000)(114,748,000)(112,633,000)(110,764,000)(107,607,000)
Warrants and rights outstanding    817,000  
Other undisclosed equity, attributable to parent    (817,000)  
Total equity:(2,589,000)154,000(712,000)1,291,000(2,625,000)441,000
TOTAL LIABILITIES AND EQUITY:2,195,0003,883,0002,965,0005,118,0001,768,0003,220,000

Income Statement (P&L) (USD)

6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
Operating expenses(3,241,000)(2,625,000)(2,634,000)(3,038,000)(3,695,000)(3,033,000)
Operating loss:(3,241,000)(2,625,000)(2,634,000)(3,038,000)(3,695,000)(3,033,000)
Nonoperating income (expense)389,000(128,000)519,0001,169,000538,000(339,000)
Interest and debt expense(5,000)     
Loss from continuing operations before income taxes:(2,857,000)(2,753,000)(2,115,000)(1,869,000)(3,157,000)(3,372,000)
Other undisclosed loss from continuing operations  (266,000)   (475,000)
Loss from continuing operations:(2,857,000)(3,019,000)(2,115,000)(1,869,000)(3,157,000)(3,847,000)
Other undisclosed net income (loss) 5,000266,000 (3,157,000) 475,000
Net loss:(2,852,000)(2,753,000)(2,115,000)(5,026,000)(3,157,000)(3,372,000)
Other undisclosed net income attributable to parent   3,157,000  
Net loss available to common stockholders, diluted:(2,852,000)(2,753,000)(2,115,000)(1,869,000)(3,157,000)(3,372,000)

Comprehensive Income (USD)

6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
Net loss:(2,852,000)(2,753,000)(2,115,000)(5,026,000)(3,157,000)(3,372,000)
Comprehensive loss, net of tax, attributable to parent:(2,852,000)(2,753,000)(2,115,000)(5,026,000)(3,157,000)(3,372,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: